<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02826629</url>
  </required_header>
  <id_info>
    <org_study_id>D16-P01</org_study_id>
    <nct_id>NCT02826629</nct_id>
  </id_info>
  <brief_title>&quot;Manual Dexterity and Oculomotor Control in Schizophrenia&quot;</brief_title>
  <acronym>MADOCS</acronym>
  <official_title>&quot;MADOCS: Manual Dexterity and Oculomotor Control as Vulnerability Markers in Schizophrenia&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier St Anne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Paris 5 - Rene Descartes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier St Anne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators recently showed that visuomotor integration was significantly altered in
      schizophrenic patients during: (i) a grip force task (Teremetz et al., 2014), and (ii) a
      saccadic paradigm (oculomotor task)(Amado et al., 2008). Given this findings, the
      investigators propose a combined study of oculomotor and grip force control to better
      characterize the sensorimotor integration deficit. This approach may allow for identification
      of behavioural biomarkers of vulnerability to develop schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1 - Scientific background and rational Use of sensory cues is essential for execution and
      correction of voluntary movements. The motor areas and their regulation is of special
      interest in patients with schizophrenia as there is clear evidence of motor abnormalities
      independent of the effects of antipsychotic medication, even before the onset of the
      disorder. Sensorimotor abnormalities have been proposed as a valid endophenotype in
      schizophrenia. Our global objective is to study and provide vulnerability markers for
      schizophrenia.

        1. Control of manual dexterity will be assessed by a force sensor (Power Grip Manipulandum,
           PGM)

        2. Oculomotor movements during behavioral task will be recorded using a video-oculography
           device

        3. The involvement of cortical inhibition in this volitional inhibition task will be
           studied by neuronavigation guided TMS coupled to EMG recording

      2 - Description of the project methodology There is strong evidence for schizophrenia being a
      neuro-developmental disorder (Rapoport et al., 2005). It has been shown, for many years, that
      patients with schizophrenia exhibit abnormal patterns of sensorimotor integration (Manschreck
      et al., 1982), which is the capacity to integrate different sensory stimuli into appropriate
      motor actions. It is clinically relevant, in terms of early diagnosis and prevention, whether
      deficient sensorimotor integration is present in the prodromal phase of schizophrenia, and
      whether this constitutes a vulnerability marker for the disease.

      Our global objective is to study the interactions and related substratum of oculomotor
      movements during force control task.

      The secondary objectives:

      (i) To show that increased motor noise is indeed present in schizophrenia. (ii) To show by
      TMS that cortical excitability in the primary motor cortex (M1) is task-modulated and
      decreased in schizophrenia.

      (iii) Assess the role of deficient cortical inhibition in these behavioral deficits To this
      end, three different groups of subjects will be studied: schizophrenic patients, non-affected
      siblings, ultra high risk patients, non-treated schizophrenic patients and healthy control
      subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Behavioural assessment</measure>
    <time_frame>BASELINE</time_frame>
    <description>Index reflecting motor performance during visuomotor task (including force and oculomotor control)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical scale : PANSS</measure>
    <time_frame>BASELINE</time_frame>
    <description>Positive and Negative Syndrome Scale: Assess positive and negative symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical scale : DIGS III</measure>
    <time_frame>BASELINE</time_frame>
    <description>Diagnostic Interview for Genetic Studies 3.0: Overview of clinical state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical scale : BPRS</measure>
    <time_frame>BASELINE</time_frame>
    <description>Brief Psychiatric Rating Scale: Assess schizophrenic symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical scale : SAS</measure>
    <time_frame>BASELINE</time_frame>
    <description>Simpson Angus Extra-Pyramidal Scale: Asses extra-pyramidal signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical scale : AIMS</measure>
    <time_frame>BASELINE</time_frame>
    <description>Abnormal Involuntary Movements Scale: Assess abnormal involuntary movements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical scale : TAP</measure>
    <time_frame>BASELINE</time_frame>
    <description>Test battery for Attentional Performance: Assess attentional capacity (e.g. working memory)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical scale : Stroop</measure>
    <time_frame>BASELINE</time_frame>
    <description>Stroop color naming test: Assess selective attention or inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical scale : WASI</measure>
    <time_frame>BASELINE</time_frame>
    <description>Wechsler Abbreviated Scale of Intelligence: Assess intelligence quotient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tracking performance (motor task): RMS Error</measure>
    <time_frame>BASELINE</time_frame>
    <description>RMS Error (Root Mean Square)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tracking performance (motor task): Coefficient of variability</measure>
    <time_frame>BASELINE</time_frame>
    <description>Coefficient of variability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tracking performance (motor task): Timing</measure>
    <time_frame>BASELINE</time_frame>
    <description>Timing/inhibition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocolomotor performance (eye tracker) : Saccade</measure>
    <time_frame>BASELINE</time_frame>
    <description>Saccade error (back up/ catch up saccades) during smooth pursuit and fixation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocolomotor performance (eye tracker): Gain</measure>
    <time_frame>BASELINE</time_frame>
    <description>Gain (target velocity/gaze velocity), Reaction time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocolomotor performance (eye tracker): Amplitude of eye movements</measure>
    <time_frame>BASELINE</time_frame>
    <description>Amplitude (°) and velocity (°/s) of saccadic movements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor noise</measure>
    <time_frame>BASELINE</time_frame>
    <description>Variability of EMG response during visuomotor task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical excitability (MEP; TMS)</measure>
    <time_frame>BASELINE</time_frame>
    <description>Motor evoked potential (MEP) during visuomotor task (single pulse TMS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical inhibition (SICI; TMS)</measure>
    <time_frame>BASELINE</time_frame>
    <description>Cortical inhibition measured during visuomotor task (paired-pulse TMS; MEP)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Schizophrenia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>40 patients with diagnosis of schizophrenia (25 medicated - 15 non-medicated)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy sibling</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>25 healthy siblings</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultra high risk for developing Schizophrenia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>15 patients with ultra high risk for developing Schizophrenia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>-25 age and gender-matched healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Manual dexterity</intervention_name>
    <description>Control of manual dexterity will be assessed by a force sensor (Power Grip Manipulandum, PGM)</description>
    <arm_group_label>Schizophrenia</arm_group_label>
    <arm_group_label>Healthy sibling</arm_group_label>
    <arm_group_label>Ultra high risk for developing Schizophrenia</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Oculomotor movements</intervention_name>
    <description>Oculomotor movements during behavioral task will be recorded using a video-oculography device</description>
    <arm_group_label>Schizophrenia</arm_group_label>
    <arm_group_label>Healthy sibling</arm_group_label>
    <arm_group_label>Ultra high risk for developing Schizophrenia</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TMS coupled to EMG recording</intervention_name>
    <description>The involvement of cortical inhibition in this volitional inhibition task will be studied by neuronavigation guided TMS coupled to EMG recording</description>
    <arm_group_label>Schizophrenia</arm_group_label>
    <arm_group_label>Healthy sibling</arm_group_label>
    <arm_group_label>Ultra high risk for developing Schizophrenia</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Psychopathological evaluations</intervention_name>
    <arm_group_label>Schizophrenia</arm_group_label>
    <arm_group_label>Healthy sibling</arm_group_label>
    <arm_group_label>Ultra high risk for developing Schizophrenia</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neuropsychological evaluations</intervention_name>
    <arm_group_label>Schizophrenia</arm_group_label>
    <arm_group_label>Healthy sibling</arm_group_label>
    <arm_group_label>Ultra high risk for developing Schizophrenia</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All groups:

               1. 18&gt;yrs&lt;50

               2. Medical visit completed

               3. Visual acuity (9/10 for each eye or corrected)

               4. Provided written informed consent

          -  Group of patient suffering from schizophrenia:

             4. DSM-IV-TR diagnostic criteria for schizophrenia 5. Treatment: stable atypical
             anti-psychotic medication for &gt;3 months prior to the study

          -  Group of UHR patient:

             6. 18&gt;yrs&lt;30 7. Fulfill at risk criteria of CAARMS diagnostic tool

        Exclusion Criteria:

        • All groups:

          1. IQ&lt;70,

          2. Contraindications for TMS protocol: no previous history of neurosurgery or seizures or
             1st degree relative with history of seizures, heart disease, drug abuse or addiction
             in the last 12 months, medications that lower seizure threshold including clozapine,
             bupropion, méthadone or theophylline.

          3. Metallic implant in head (except dental fillings)

          4. Pacemaker, or other electronic implanted devices

          5. Central neurological disease: parkinsonism, x

          6. Severe heart attack

          7. Instable clinical state (e.g. stroke)

          8. Previous history of drug abuse lasting more than 5 years or during the last year

          9. Life event with a moderate to severe impact

         10. Caffeine intake in the last two hours preceding visuomotor assessment

             • Groups of Siblings and Healthy controls:

         11. No previous history of psychiatric disease, psychotic spectrum disorder (according to
             DIGS 3.0)

         12. No previous history of antipsychotic medication (entire life)

             • Groups of UHR patient:

         13. Chlorpromazine dose &gt;100mg over more than 12 weeks

         14. No previous history of autism spectrum disorder, bipolar disorder or diagnozed
             schizophrenia (according to DSM-IV-TR criteria), isolated anxiety disorders (e.g.
             social phobia, agoraphobia)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle Amado, Dr</last_name>
    <role>Study Director</role>
    <affiliation>CHSA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pavel Lindberg, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabelle Amado, Dr</last_name>
    <phone>00 33 1 45 65 81 79</phone>
    <email>i.amado@ch-sainte-anne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie GODARD</last_name>
    <phone>00 33 1 45 65 77 28</phone>
    <email>marie.godard@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de Recherche Clinique (CRC) - CHSA</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Macarena CUENCA</last_name>
      <email>m.cuenca@ch-sainte-anne.fr</email>
    </contact>
    <contact_backup>
      <last_name>Cecile Bergot</last_name>
      <phone>00 33 1 45 65 84 90</phone>
      <email>c.bergot@ch-sainte-anne.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Macarena CUENCA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service Hospitalo-Universitaire (SHU) - CHSA</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle Amado</last_name>
      <phone>00 33 1 45 65 81 79</phone>
      <email>i.amado@ch-sainte-anne.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marie GODARD</last_name>
      <phone>00 33 1 45 65 77 28</phone>
      <email>marie.godard@aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Isabelle Amado</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Teremetz M, Amado I, Bendjemaa N, Krebs MO, Lindberg PG, Maier MA. Deficient grip force control in schizophrenia: behavioral and modeling evidence for altered motor inhibition and motor noise. PLoS One. 2014 Nov 4;9(11):e111853. doi: 10.1371/journal.pone.0111853. eCollection 2014.</citation>
    <PMID>25369465</PMID>
  </reference>
  <reference>
    <citation>Amado I, Landgraf S, Bourdel MC, Leonardi S, Krebs MO. Predictive saccades are impaired in biological nonpsychotic siblings of schizophrenia patients. J Psychiatry Neurosci. 2008 Jan;33(1):17-22.</citation>
    <PMID>18197268</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2016</study_first_submitted>
  <study_first_submitted_qc>July 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sensorimotor Integration</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>TMS</keyword>
  <keyword>Oculomotor</keyword>
  <keyword>Motor Control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

